UBS Group
IPCI

UBS Group’s Intellipharmaceuticals International Inc. IPCI Stock Holding History

UBS Group’s Portfolio IPCI Stock Details IPCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-40
Closed -$1K – 9712
2014
Q4 		$1K Buy
+40
New +$1.08K ﹤0.01% 9586

Other funds holding IPCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
FANJ
Financial Architects (New Jersey) Marlton, New Jersey $663M AUM 15.53% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group's IPCI Position: Q3 2018 in Review

UBS Group sold out of Intellipharmaceuticals International Inc. (IPCI) in Q3 2018, closing a stake of 2,339 shares — an estimated $10K sold.

UBS Group first reported a position in IPCI in Q4 2014 and held it in 6 quarters. The position peaked at $19K in Q4 2016. 10 funds tracked by Wall St. Rank hold IPCI as of Q3 2018.

  • UBS Group reported no remaining Intellipharmaceuticals International Inc. position as of Q3 2018 after selling out during the quarter.
  • UBS Group sold 2,339 Intellipharmaceuticals International Inc. shares in Q3 2018, an estimated $10K.
  • UBS Group first reported a position in Intellipharmaceuticals International Inc. in Q4 2014 and held it in 6 quarters.
  • UBS Group's Intellipharmaceuticals International Inc. position peaked at $19K in Q4 2016.
  • 10 funds tracked by Wall St. Rank held Intellipharmaceuticals International Inc. as of Q3 2018.

Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.